Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.78
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.78
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume5.68M
Average Volume (3M)22.44M
Market Cap
$1.56B
Enterprise Value$1.04K
Total Cash (Recent Filing)$654.47M
Total Debt (Recent Filing)$72.38M
Price to Earnings (P/E)―
Beta3.28
Next Earnings
Aug 11, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding524,677,860
10 Day Avg. Volume26,162,671
30 Day Avg. Volume22,443,950
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.38Price Target Upside95.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$59.12M
Bulls Say, Bears Say
Bulls Say
Balance Sheet & RunwayA sizable cash balance and explicit runway into early 2028, together with a guided sub-$390M 2026 cash opex target and reported ~30% YoY opex reduction, materially extend the company’s ability to fund clinical programs and deliver catalysts over the next 12–18 months without immediate financing.
Partnership Traction & Milestone RevenueSustained partner inflows and delivered milestones provide recurring non-dilutive funding and validation of the platform from large pharma. This commercial partnership pipeline cushions R&D spending, spreads development risk, and creates optionality for future revenue streams tied to partner opt‑ins and royalties.
Platform Scale & EfficiencyLarge proprietary datasets and claimed efficiency gains (far fewer compounds synthesized and faster candidate progression) represent durable competitive advantages in discovery. If reproducible, these structural efficiencies lower per‑program cost and time, improving long‑term R&D productivity and partner value.
Bears Say
Cash Burn & Weak Cash FlowPersistent negative operating and free cash flow (TTM ~-$321M) means the business remains reliant on external funding or partner payments. Over the medium term this raises dilution and financing risk if milestone timing or partner inflows slip, constraining ability to expand programs or commercialize independently.
No Approved Products; Platform-to-revenue UnprovenDespite platform claims and clinical proofs, Recursion has no marketed products. Long‑term revenue depends on converting clinical readouts into approvals or partner commercial programs; until that translation occurs, the business model remains milestone-driven and exposed to binary clinical/regulatory outcomes.
Regulatory & Clinical Timing RiskBeing first‑in‑disease for REC‑4881 creates regulatory pathway uncertainty and design challenges. Key readouts and dose‑escalation data are pending across multiple programs; delays or unclear regulatory feedback could push timelines, pressure runway, and increase the chance that clinical progress does not convert into timely approvals or commercial partnerships.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $1.56B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.045.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -0.24.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Recursion Pharmaceuticals, Inc has 524,677,860 shares outstanding.
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went up 1.78%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.38 (95.11% Upside)
$7.38 (95.11% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Stock 12 Month Forecast
Average Price Target
$7.38
▲(95.11% Upside)
Technical Analysis
Ownership Overview
2.98% Insiders
12.97% Mutual Funds
0.10% Other Institutional Investors
56.72% Public Companies and Individual Investors